Ceftriaxone
Product Images NDC 57297-644

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Ceftriaxone (NDC 57297-644). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Ceftriaxone (Ceftriaxone Figure 01)

FDA Label Image

Ceftriaxone For Injection Usp250 mg Rx Onlyndc 68180-611-01 1 Vial In 1 Box (Ceftriaxone Figure 02)

Ceftriaxone For Injection Usp250 mg Rx Onlyndc 68180-611-01							1 Vial In 1 Box (Ceftriaxone Figure 02)
This is a pharmaceutical product called Ceftriaxone for Injection USP, produced by Lupin Pharmaceuticals, Inc. It comes in a single-use vial with 250 mg of sterile ceftriaxone sodium USP. It is only for M. or LV. use and must be kept away from light. The product is only available with a prescription and all instructions for dosage and administration can be found in the package insert. The product must be stored at 20°25°C (68°-77°F) before reconstitution.*
FDA Label Image

Ceftriaxone For Injection Usp500 mg Rx Onlyndc 68180-622-01 1 Vial In 1 Box (Ceftriaxone Figure 03)

Ceftriaxone For Injection Usp500 mg Rx Onlyndc 68180-622-01							1 Vial In 1 Box (Ceftriaxone Figure 03)
This is a pharmaceutical product called Ceftriaxone for Injection USP, packaged in a single-use vial with NDC number 68180-622-01. It is a sterile powder containing ceftriaxone sodium USP equivalent to 500 mg of ceftriaxone, intended for intramuscular or intravenous administration, and should only be used with a prescription. Before reconstitution, it should be stored at a controlled room temperature of 20°C-25°C. After reconstitution, storage should follow the instructions on the package insert. The manufacturer is Lupin Pharmaceuticals, Inc. of Baltimore, Maryland, and it is manufactured by Lupin Limited of Mandideep 462 046 INDIA.*
FDA Label Image

Ceftriaxone For Injection Usp1 G Rx Onlyndc 68180-633-01 1 Vial In 1 Box (Ceftriaxone Figure 04)

Ceftriaxone For Injection Usp1 G Rx Onlyndc 68180-633-01							1 Vial In 1 Box (Ceftriaxone Figure 04)
This is a description of a single-use vial containing sterile ceftriaxone sodium USP equivalent to ceftriaxone 1 g. It is intended for LM or LV use only and should be reconstituted with 2.1 mL 1% Lidocaine Hydrochloride Injection (USP) or Sterile Water for Injection (USP) for IM administration. Each mL of solution contains approximately 350 mg of ceftriaxone. The usual dosage is described in the package insert. The powder should be stored at controlled room temperature before reconstitution and protected from light. The storage after reconstitution is described in the package insert. The product is manufactured by Lupin Limited in India and distributed by Lupin Pharmaceuticals in the United States. The lot number is 218084.*
FDA Label Image

Ceftriaxone For Injection Usp2 G Rx Onlyndc 68180-644-01 1 Vial In 1 Box (Ceftriaxone Figure 05)

Ceftriaxone For Injection Usp2 G Rx Onlyndc 68180-644-01							1 Vial In 1 Box (Ceftriaxone Figure 05)
This is a description of a single-use vial of Ceftriaxone for Injection USP, which is a medication used for intramuscular or intravenous use. The vial contains sterile ceftriaxone sodium USP equivalent to ceftriaxone 2. The usual dosage and instructions on how to reconstitute the vial are provided in the package insert. The medication should be protected from light and stored as specified in the package insert. The vial is manufactured by Lupin Pharmaceuticals, Inc. in the United States and by Lupin Limited in India. The text also includes important information such as NDC, lot number, and size.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.